Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
91
Views
0
CrossRef citations to date
0
Altmetric
RESEARCH LETTER

Impact of Baseline Lung Function on Future Exacerbations in Patients with Moderate-to-Severe Asthma

Asif H Khan1 Sanofi, Chilly-Mazarin, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9158-0116View further author information
ORCID Icon,
Cori Gray2 Sanofi, Cambridge, MA, USAView further author information
,
Laurent Eckert1 Sanofi, Chilly-Mazarin, FranceView further author information
,
Caroline Amand1 Sanofi, Chilly-Mazarin, FranceView further author information
,
Jaman Maroni3 Regeneron Pharmaceuticals Inc, Tarrytown, NY, USAView further author information
,
Zhixiao Wang3 Regeneron Pharmaceuticals Inc, Tarrytown, NY, USAView further author information
,
Bethan Jones4 Pharmatelligence, Cardiff, UKORCID Iconhttps://orcid.org/0000-0003-1954-9362View further author information
ORCID Icon,
Thomas Berni4 Pharmatelligence, Cardiff, UKView further author information
,
Christopher Ll Morgan4 Pharmatelligence, Cardiff, UKView further author information
&
Paul J Rowe5 Sanofi, Bridgewater, NJ, USAView further author information
 show all
Pages 1639-1644 | Received 20 May 2022, Accepted 30 Sep 2022, Published online: 11 Nov 2022

References

  • Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: http://www.ginasthma.org/. Accessed February 22, 2022.
  • James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med. 2005;171(2):109–114. doi:10.1164/rccm.200402-230OC
  • Krings JG, Goss CW, Lew D, et al. Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: results from SARP-3. J Allergy Clin Immunol. 2021;148(3):752–762. doi:10.1016/j.jaci.2021.01.029
  • Matsunaga K, Hirano T, Oka A, et al. Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations. J Allergy Clin Immunol Pract. 2015;3(5):759–764 e1. doi:10.1016/j.jaip.2015.05.005
  • Tupper OD, Ulrik CS. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021;22(1):269. doi:10.1186/s12931-021-01864-z
  • Knuiman MW, James AL, Divitni ML, et al. Lung function, respiratory symptoms, and mortality: results from the Busselton Health Study. Ann Epidemiol. 1999;9(5):297–306. doi:10.1016/S1047-2797(98)00066-0
  • Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004;126(6):1875–1882. doi:10.1378/chest.126.6.1875
  • Hansen EF, Vestbo J, Phanareth K, Kok-Jensen A, Dirksen A. Peak flow as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(3 Pt 1):690–693. doi:10.1164/ajrccm.163.3.2006120
  • Clinical Practice Research Datalink (CPRD) | UK data driving real-world evidence; 2019. Available from: https://www.cprd.com/. Accessed February 15, 2022.
  • World Health Organization. International statistical classification of diseases and related health problems 10th revision; 2010. Availabe from: https://icd.who.int/browse10/2010/en#/X. Accessed February 15, 2022.
  • British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma (101): a national clinical guideline; 2011. Available from: http://globalasthmanetwork.org/management/guides/bosnia_and_herzegovina/British%20guideline%20for%20asthma.pdf. Accessed February 22, 2022.
  • Education National Asthma and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138. doi:10.1016/j.jaci.2007.09.029
  • Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322–1333. doi:10.1183/13993003.00780-2015
  • Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321. doi:10.1183/13993003.00779-2015
  • Ilmarinen P, Juboori H, Tuomisto LE, Niemela O, Sintonen H, Kankaanranta H. Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma. Sci Rep. 2019;9(1):16107. doi:10.1038/s41598-019-52361-9
  • Why asthma still kills: the National Review of Asthma Deaths (NRAD) confidential enquiry report. London: Royal College of Physicians; 2014. Available from: http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf. Accessed March 7, 2022.
  • Levy ML. The national review of asthma deaths: what did we learn and what needs to change? Breathe. 2015;11(1):14–24. doi:10.1183/20734735.008914
  • Enright PL, Lebowitz MD, Cockroft DW. Physiologic measures: pulmonary function tests. Asthma outcome. Am J Respir Crit Care Med. 1994;149(2 Pt 2):S9–S18; discussion S19–S20. doi:10.1164/ajrccm/149.2_Pt_2.S9
  • Zeiger RS, Yegin A, Simons FE, et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol. 2012;108(2):81–87. doi:10.1016/j.anai.2011.12.001
  • Patel M, Pilcher J, Reddel HK, et al. Predictors of severe exacerbations, poor asthma control, and beta-agonist overuse for patients with asthma. J Allergy Clin Immunol Pract. 2014;2(6):751–758. doi:10.1016/j.jaip.2014.06.001
  • Papaioannou AI, Kostikas K, Bakakos P, et al. Predictors of future exacerbation risk in patients with asthma. Postgrad Med. 2016;128(7):687–692. doi:10.1080/00325481.2016.1220807
  • Chipps BE, Zeiger RS, Borish L, et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012;130(2):332–342 e310. doi:10.1016/j.jaci.2012.04.014
  • Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet. 1999;353(9150):364–369. doi:10.1016/S0140-6736(98)06128-5

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.